08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Insight Genetics, Qiagen deal

Insight granted Qiagen exclusive, worldwide rights to ret proto-oncogene (RET) , c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1) and DEP domain containing 1 (DEPDC1) biomarkers as an aid in diagnosing non-small cell lung cancer (NSCLC)...